Teleflex (NYSE:TFX) released its quarterly earnings data on Thursday. The medical technology company reported $1.93 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.68, MarketWatch Earnings reports. The business had revenue of $567.00 million during the quarter, compared to the consensus estimate of $537.85 million. Teleflex had a return on equity of 18.96% and a net margin of 21.12%. The firm’s revenue was down 13.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.66 earnings per share.

Shares of TFX stock traded down $22.73 on Thursday, hitting $378.26. 6,113 shares of the stock were exchanged, compared to its average volume of 163,643. The company has a current ratio of 3.60, a quick ratio of 2.38 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $17.32 billion, a P/E ratio of 32.11, a price-to-earnings-growth ratio of 2.93 and a beta of 1.01. The business has a 50-day moving average of $367.07 and a 200 day moving average of $350.42. Teleflex has a fifty-two week low of $221.27 and a fifty-two week high of $405.07.

A number of equities research analysts recently commented on TFX shares. Needham & Company LLC reiterated a “buy” rating and issued a $431.00 price objective on shares of Teleflex in a report on Thursday, April 30th. JMP Securities lowered their price target on Teleflex from $395.00 to $385.00 and set a “market outperform” rating for the company in a report on Friday, May 1st. SVB Leerink increased their price target on Teleflex from $400.00 to $425.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. Morgan Stanley increased their price target on Teleflex from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Finally, Wells Fargo & Co increased their price target on Teleflex from $365.00 to $375.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $383.40.

In related news, CAO John Deren sold 1,093 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $330.10, for a total transaction of $360,799.30. Following the completion of the transaction, the chief accounting officer now directly owns 1,253 shares of the company’s stock, valued at $413,615.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $386.35, for a total value of $77,270.00. Following the transaction, the director now directly owns 1,321 shares of the company’s stock, valued at $510,368.35. The disclosure for this sale can be found here. 2.21% of the stock is owned by corporate insiders.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

See Also: What is insider trading?

Earnings History for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.